1	The persistent underrepresentation of patients with chronic kidney disease in
2	cardiovascular trials: a systematic review and evidence map of exclusion and
3	outcomes
4	
5	Julia M.T. Colombijn ^{1,2} , Demy L. Idema ³ , Sanne van Beem ¹ , Anna Marthe Blokland ¹ , Kim van
6	der Braak ³ , M. Louis Handoko ^{4,5} , Linde F. Huis in 't Veld ³ , Tabea Kaul ² , Nurda Kolagasigil-
7	Akdemir ¹ , Mike P.T. Kusters ³ , Sabine C.A. Meijvis ¹ , Ilse J. Oosting ^{1,2} , Rene Spijker ^{3,6} , Michiel
8	L. Bots ² ; Lotty Hooft ³ , Marianne C. Verhaar ¹ , Robin W.M. Vernooij ^{1,2}
9	
10	1 Department of Nephrology & Hypertension, University Medical Center Utrecht, Utrecht, the
11	Netherlands
12	2 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
13	Utrecht University, Utrecht, the Netherlands
14	3 Cochrane Netherlands, Julius Center for Health Sciences and Primary Care, University
15	Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
16	4 Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam
17	Cardiovascular Sciences, Amsterdam, the Netherlands
18	5 Amsterdam Cardiovascular Sciences (Heart Failure & Arrhythmias), Amsterdam, The
19	Netherlands
20	6 Medical Library, Amsterdam UMC, University of Amsterdam, Amsterdam Public Health,
21	Amsterdam, Netherlands
22	
23	Corresponding author: Dr. Robin W.M. Vernooij
24	Visiting address: Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
25	Tel: +31 (0)88 75 555 55
26	Email adress: <u>r.w.m.vernooij-2@umcutrecht.nl</u>
27	Sponsor: Dutch Heart Foundation, 2020B008 RECONNEXT
28	Number of tables: 1

- 29 Number of figures: 5
- 30 Abstract word count: 320
- 31 Word count: 3451
- 32 Keywords: Cardiovascular disease, cardiovascular risk management, chronic kidney
- 33 disease, kidney failure, systematic review
- 34

35 Abstract

36	Background: Patients with chronic kidney disease (CKD) are at high risk for cardiovascular
37	disease, but their systematic underrepresentation in cardiovascular randomised controlled
38	trials (RCTs) limits appropriate evidence to guide cardiovascular risk management (CVRM).
39	This systematic review aims to evaluate trends in the underrepresentation of patients with
40	CKD in cardiovascular RCTs in the past 20 years and highlight evidence gaps for CVRM
41	medications in this population.
42	
43	Methods: A systematic search was conducted in ClinicalTrials.gov from its inception in 2000
44	until October 2021, targeting RCTs evaluating the efficacy of CVRM medications on
45	mortality, cardiovascular disease, and kidney failure in adults with cardiovascular disease or
46	one or more cardiovascular risk factors. Two reviewers independently screened references
47	and extracted data. Outcomes were the exclusion rate of patients with CKD over time and an
48	evidence map of studies reporting results for this population.
49	
50	Results: In total, 1194 RCTs involving 2,207,677 participants were included. Since 2000, the
51	percentage of cardiovascular RCTs that exclude patients with CKD has increased from 66%
52	to 79% (74% overall, 884 RCTs). In 73% of RCTs, more patients were excluded than
53	anticipated on safety grounds (63% without dose adjustment necessary and 79% of RCTs

54 with dose adjustment necessary). In total, 158 RCTs (13%) reported results patients with

55 CKD separately (e.g. in subgroup analyses). Significant evidence gaps exist for most CVRM
 56 interventions for patients with CKD, particularly for those with CKD stage 4-5. For patients

57 with an eGFR <30 ml/min/1.73 m^2 , 23 RCTs reported results, for dialysis patients 15 RCTs,

58 and for kidney transplant patients only 1 RCT.

59

60 <u>Conclusion:</u> The underrepresentation of patients with CKD in cardiovascular RCTs has not 61 improved in the past two decades and three-quarters of RCTs excluded more patients than 62 expected on safety grounds. A lack of RCTs that report results for patients with CKD has

- 63 resulted in significant evidence gaps for most CVRM medications in all subgroups of patients
- 64 with CKD, in particular for those with CKD stage 4-5.

65

- 66 <u>Primary funding source:</u> Dutch Heart Foundation, 2020B008 RECONNEXT
 67
- 68 <u>Registration:</u> PROSPERO (CRD42022296746)

70 Introduction

71

72	Chronic kidney disease (CKD) affects almost 700 million patients worldwide and is the cause
73	of 1.9 million cardiovascular deaths annually (1, 2). Over 60% of patients with CKD has a
74	history of cardiovascular disease and this is also the main cause of death in this population
75	(3, 4). Almost all patients with CKD have a much higher risk for CVD than for kidney failure
76	(5, 6). This elevated CVD risk is already observed for patients with an estimated glomerular
77	filtration rate (eGFR) <75 ml/min/1.73m ² and increases as CKD progresses, independently of
78	other risk factors like hypertension and diabetes (3, 7).
79	
80	The high cardiovascular risk in patients with CKD underscores the importance of effective
81	strategies for cardiovascular risk management (CVRM) for patients with CKD. Nevertheless,
82	even though over 90% of patients with CKD are being prescribed CVRM medications,
83	evidence on the safety and efficacy of these medications in patients with CKD is limited (8,
84	9), Historically, patients with CKD largely have been underrepresented in cardiovascular
85	randomised controlled trials (RCTs). They are frequently excluded due to concerns about the
86	safety and efficacy of interventions. Even the RCTs without explicit CKD exclusion criteria
87	often do not include these patients nor assess treatment effects for them (10-13).
88	
89	A lack of information about the efficacy of CVRM medications in people with CKD
90	undermines effective CVRM treatment. Efficacy estimates about CVRM medications from
91	RCTs excluding patients with CKD cannot be extrapolated carelessly since the increased
92	CVD risk in patients with CKD and altered pathophysiology of CVD can modify the efficacy of
93	treatments (14). As CKD progresses to kidney failure, patients' CVD burden shifts from
94	atherosclerotic CVD to medial arterial calcification, cardiac arrhythmias, left-ventricular
95	hypertrophy, and sudden cardiac death (14). A higher cardiovascular risk could enhance the
96	efficacy of CVRM treatments for patients with CKD as a greater absolute risk reduction can
97	be achieved. However, a reduced life expectancy and the induction of additional pathways in

98 CVD pathophysiology which are not inhibited by traditional CVRM medications could offset

99 these benefits and render treatment futile (15).

- 100
- 101 Several systematic reviews, which included RCTs published up to 2014, have reported on
- 102 the underrepresentation of patients with CKD in cardiovascular RCTs (10-13). However, it is
- 103 unclear whether the representation of patients with CKD in cardiovascular RCTs has
- 104 improved over the past years and whether this population has been included in RCTs
- 105 evaluating the efficacy of (relatively) new treatments, such as sodium glucose-cotransporter-
- 106 2 inhibitors (SGLT2-inhibitors) and direct oral anticoagulants (DOACs). Furthermore, the
- 107 systematic exclusion of patients with CKD makes it uncertain for which CVRM medications
- 108 evidence is available on the efficacy and safety specifically for people with CKD. An overview
- 109 of the RCTs evaluating the efficacy of CVRM medications for (different subgroups of)
- 110 patients with CKD is currently lacking. Therefore, the aim of this systematic review was to
- 111 evaluate trends in the underrepresentation of patients with CKD from cardiovascular RCTs in
- 112 the past 20 years, and to create an overview of the available evidence, highlighting evidence
- 113 gaps for CVRM medications for patients with CKD.

114 Methods

- 115 This systematic review has been reported according to the Preferred Reporting Items for
- 116 Systematic Reviews and Meta-Analyses (PRISMA) and registered prospectively in
- 117 PROSPERO (CRD42022296746) (16). The full protocol has been published previously (17).
- 118

119 Data sources and searches

- 120 In brief, ClinicalTrials.gov was searched through the Cochrane Central Register of Controlled
- 121 Trials from inception (February 2000) until October 2021 with a combination of keywords for
- 122 CVD, cardiovascular risk factors and the included interventions to identify planned, ongoing,
- 123 terminated, and completed RCTs. Next, the full-text publications were retrieved up to May
- 124 2023 from ClinicalTrials.gov. If no full texts were listed in ClinicalTrials.gov, MEDLINE,
- 125 Embase, and Google Scholar were searched additionally to retrieve the full texts. Records of
- 126 $\,$ which no publications could be found were excluded. Landmark RCTs not identified in our
- 127 search were added manually.
- 128

129 Study selection

- 130 Two reviewers screened clinical trial records and publications independently based on the
- 131 eligibility criteria. Disagreements were resolved by discussion.
- 132

133 Eligible RCTs were those evaluating the effect of antiplatelets, anticoagulants, blood

- 134 pressure-lowering drugs, glucose-lowering drugs, or cholesterol-lowering drugs
- 135 recommended by the European Society of Cardiology, the American Heart Association, the
- 136 American Stroke Association, the American College of Cardiology, and the American
- 137 Diabetes Association for the prevention of CVD (18-39) on all-cause or cardiovascular
- 138 mortality, cardiovascular disease (as composite endpoint and individual events), peripheral
- 139 arterial disease, or kidney failure, in adults with a history of CVD or one or more CVD risk
- 140 factors. Interventions must be compared against placebo, usual care, another therapy, or a
- 141 different treatment dosage or duration.

- 142
- 143 Data extraction and quality assessment

144	Data extraction was	performed by one	e reviewer with	a standardised	extraction form and
-----	---------------------	------------------	-----------------	----------------	---------------------

- 145 verified by a second reviewer. A list of extracted variables is described in the protocol (17).
- 146 Risk of bias was not assessed since bias in study design is unlikely to affect whether patients
- 147 with CKD are excluded from RCTs or whether authors report results for them (as subgroup
- 148 analysis or by restriction of the study population).
- 149
- 150 Data synthesis and analysis
- 151 Outcomes of interest were the frequency of exclusion of patients with CKD and the reporting
- 152 of results for patients with CKD (through subgroup analyses or restriction of the study
- 153 population). Exclusion of patients with CKD was defined as the exclusion of patients on
- 154 kidney-related eligibility criteria. If RCTs did not specify kidney-related eligibility criteria, we
- 155 presumed these patients were not excluded.
- 156

157 Categorical variables were described as frequency (percentage) and continuous variables as

158 mean (standard deviation) if they followed a normal distribution and otherwise as median

159 [interquartile range]. The frequency of exclusion of patients with CKD was evaluated for

160 different time periods, medications, and dosing recommendations for patients with CKD.

161 Dosing recommendations were categorised based on the Renal Drug Handbook as no dose

adjustment necessary, dose adjustment in CKD stage 3, or 4-5, and contra-indicated in CKD

163 stage 4, or 5 (40).

164 **Results**

165 Study selection, and characteristics of studies and participants

- 166 Overall, 13,017 RCTs were identified in the search of which 8,780 were excluded on
- 167 ClinicalTrials.gov record. Of 1419 RCTs, no full-text was retrieved. Of the remaining 2818
- records screened on full text, 1,194 RCTs involving 2,207,677 participants were included
- 169 (Supplementary Figure 1). Main reasons for exclusion were no outcomes of interest (n=884),
- 170 no interventions of interest (n=304), and insufficient sample size (n=77). Included RCTs had
- a median follow-up of 24 months [IQR 12.0 39.6] and 82 (7%) had published a protocol
- 172 only. Glucose-lowering drugs were evaluated in 552 RCTs (46%), antiplatelets and
- 173 anticoagulants in 229 RCTs (19%), blood pressure-lowering drugs in 221 RCTs (19%), and a
- 174 combination of these interventions in 30 RCTs (3%) (Table 1).
- 175
- 176 Participants had a mean age of 63±6 years and the mean percentage of women was 36±12.
- 177 The mean eGFR was 73±13 ml/min/1.73m² and the median serum creatinine level was 1.00
- 178 [0.96-1.04] mg/dl but these variables were reported in only 295 (25%) and 154 (13%) RCTs,
- 179 respectively. Patients receiving dialysis were included in 17 RCTs (1%) and patients with a
- 180 kidney transplant in 1 (<1%) RCT. An overview of included RCTs and their characteristics is
- 181 listed in Supplemental Table 1.
- 182

183 Trends in the underrepresentation of patients with CKD

184 Since 2000, the percentage of RCTs that excluded (subgroups of) patients with CKD has

185 increased from 66 to 79% (74% overall, 884 RCTs; Figure 1a). Patients with CKD stage 1-3

- 186 (i.e., eGFR >30 ml/min/1.73m², serum creatinine <2 mg/dL or a history of CKD) were
- 187 excluded in 458 RCTs (38% of all included RCTs and 52% of RCTs which excluded patients
- 188 with CKD) (Figure 1a). In the past 20 years, patients with CKD stage 4-5 have been excluded
- 189 from cardiovascular RCTs more frequently while the exclusion of patients with CKD stage 1-
- 190 3 has remained stable (Figure 1a). The proportion of RCTs where dose adjustment based on

kidney function was required or where medication was contra-indicated on kidney function
remained consistent across this different time period (Figure 2b, Supplemental Figure 2). The
kidney exclusion criteria applied were heterogeneous, but generally based on eGFR (n=442,
50%) or serum creatinine (n=324, 37%) (Figure 1c). The exclusion of patients with CKD for
individual drug groups is illustrated in Figure 1b.

- 196
- 197 In 73% of RCTs, more patients with CKD were excluded than expected on safety grounds.
- 198 Patients with CKD were excluded in 63% of RCTs where no dose adjustment for the
- 199 interventions on kidney function was required (306/488). The rate of exclusion of patients
- 200 with CKD was over 80% in RCTs were the dose-adjustments based on kidney function were
- 201 necessary or interventions were contra-indicated based on kidney function. However, 79% of
- 202 these RCTs (558/706 RCTs) also excluded more patients with CKD than necessary on
- 203 safety grounds (Figure 2a).
- 204

205 Evidence (gaps) for CVRM medications in patients with CKD

206 In total 158 RCTs (13%) reported results for patients with CKD. Of these RCTs, 34 (3%) only

207 included patients with CKD (4 cholesterol-lowering drugs, 13 blood-pressure lowering drugs,

208 15 glucose-lowering drugs, and 2 antithrombotic drugs). The percentage of RCTs that

209 reported results for patients with CKD has not improved in the past 20 years (Figure 3b)

210 Analyses for patients with CKD were predominantly performed for composite cardiovascular

211 endpoints (112 RCTs, 66%) in heterogeneous strata (Figure 3a, 4, and 5). Few RCTs

212 conducted analyses for individual cardiovascular endpoints, particularly for heart failure,

213 peripheral arterial disease, and kidney failure (Figure 3a, Supplemental tables 3-9). RCTs

- that conducted subgroup analyses for patients with CKD had a mean baseline eGFR of
- 215 71±12 ml/min/1.73m2, although this parameter was reported in only 40% of the RCTs.
- 216
- 217 We identified significant gaps in evidence for CVRM medications for all patients with CKD.
- 218 Evidence gaps were most notable for patients with CKD stage 4-5 for whom 39 RCTs

219	reported results (23 for eGFR <30 ml/min/1.73m ² , 10895 participants; 15 for dialysis 9516
220	participants, 1 for kidney transplant recipients; 2102 participants. Figures 4 and 5). An
221	overview of analyses for endpoints other than major adverse cardiovascular events (MACE)
222	is added in the supplementary materials (Supplementary Figures 3-9).

223

224 Blood pressure-lowering drugs

- 225 Most RCTs evaluating blood pressure-lowering drugs for the prevention of major adverse
- 226 cardiovascular events (MACE) for patients with CKD studied angiotensin-converting enzyme-
- 227 inhibitors (ace-inhibitors, angiotensin receptor blockers (ARBs) and mineralocorticoid
- receptor blockers (MRAs) (Figures 4 and 5). For patients with an eGFR <60 ml/min/1.73m²,
- 229 each antihypertensive was evaluated in at least 1 RCT except for alpha-blockers. ARBs, beta
- blockers and MRAs were evaluated for both patients with an eGFR <30 ml/min/1.73m² and
- 231 patients receiving dialysis. Ace-inhibitors and calcium channel blockers were also evaluated
- for patients receiving dialysis and thiazides for patients with an eGFR <30 ml/min/1.73m².
- 233 Other antihypertensives were not evaluated in these populations. None of the RCTs
- evaluated the efficacy of antihypertensives for patients with a kidney transplant (Figures 4
- 235 and 5).

236

237 Cholesterol-lowering drugs

238 The efficacy of cholesterol-lowering drugs in patients with CKD on MACE was evaluated 239 almost exclusively for stating but barely for other cholesterol-lowering drugs (Figures 3 and 4). Statins were evaluated for patients with an eGFR <60 ml/min/ $1.73m^2$ as monotherapy or 240 241 in combination with ezetimibe. PCSK-9 (proprotein convertase subtilisin/kexin type 9) 242 inhibitors, niacin, and icosapent ethyl were also evaluated for this population but not for patients with CKD stage 4-5. For patients with an eGFR <30 ml/min/1.73m², the combination 243 244 of statins with ezetimibe was the only therapy evaluated. For patients receiving dialysis, 245 statins were evaluated as monotherapy and combination with ezetimibe. For patients with a

kidney transplant, statin monotherapy was evaluated but none of the other drugs (Figures 4

247 and 5).

248

249 Antiplatelets and anticoagulants

250 Of all CVRM medications, antiplatelets and anticoagulants were studied most frequently for

251 patients with CKD (Figures 3 and 4). At least 10 RCTs evaluated the efficacy of single

antiplatelet therapy, double antiplatelet therapy (SAPT and DAPT, respectively), and DOACs

253 for patients with CKD. However, these analyses were largely restricted to patients with an

eGFR <60 ml/min/1.73m² (Figures 3 and 4). The efficacy of triple antiplatelet therapy or

255 combinations of DAPT or SAPT with vitamin K antagonist (VKAs) or DOACs was evaluated

256 in a handful of RCTs and only one of these RCTs evaluated the efficacy of these

interventions in patients with an eGFR <60 ml/min/1.73m². For patients with an eGFR <30

258 ml/min/1.73m², the efficacy of SAPT, DAPT, DOACs, and a combination of DOACs with

259 SAPT was evaluated. For patients receiving dialysis, evidence was limited to the comparison

of DOACs with VKAs and the efficacy of antiplatelets was not evaluated at all. None of the

261 RCTs evaluated the efficacy of antiplatelets and anticoagulants for patients with a kidney

transplant (Figures 4 and 5).

263

264 Glucose-lowering drugs

265 The efficacy of newer glucose-lowering drugs (SGLT-1 inhibitors and GLP-1 receptor

agonists) on MACE for patients with CKD was evaluated in multiple RCTs. However, hardly

any evidence was available for older glucose-lowering drugs (metformin, sulphonylureas,

and insulin; Figures 3 and 4). Similarly to antiplatelets and anticoagulants, evidence was

269 mainly restricted to patients with an eGFR <60 ml/min/1.73m². For patients with an eGFR

- 270 <30 ml/min/1.73m², the efficacy of SGLT-2 inhibitors, DPP-4 inhibitors, GLP-1 receptor
- agonists, and insulin was evaluated. For patients receiving dialysis, the efficacy DPP-4
- inhibitors was compared with sulphonylureas but no other drugs were studied. None of the

273 RCTs evaluated the efficacy of glucose-lowering drugs in patients with a kidney transplant
274 (Figures 4 and 5).

275

276 Discussion

277 In our systematic review, including almost 1200 RCTs and over 2.2 million patients, we have 278 identified no improvement in the underrepresentation of patients with CKD over the past two 279 decades. On the contrary, since 2000 the number of cardiovascular RCTs that excluded 280 subgroups of patients with CKD has increased. Exclusion criteria were heterogenous and 281 cardiovascular RCTs consistently excluded a larger number of patients with CKD than would 282 be anticipated on safety grounds. In addition, only 13% of included cardiovascular RCTs 283 evaluated the efficacy of CVRM medications for patients with CKD, mostly in subgroup 284 analyses, resulting in evidence gaps across all CVRM medications and subgroups of patients 285 with CKD.

286

287 The persistently high proportion of RCTs that exclude patients with CKD in the past 20 years 288 cannot be attributed to a rise in the number of RCTs requiring dose-adjustment on kidney 289 function for CVRM medications as the proportion of RCTs requiring such adjustment 290 remained stable. While excluding patients with CKD from such RCTs due to safety concerns 291 can be justifiable, the significantly more stringent kidney exclusion criteria compared to 292 prescription thresholds in clinical practice suggest there are additional reasons for excluding 293 patients with CKD. Practical issues like the necessity for dose adjustments, concerns about 294 heterogeneity in treatment effects, or a limited life expectancy could also discourage clinical 295 trialists from including patients with CKD in their RCTs.

296

297 The evidence gaps for patients with CKD in cardiovascular RCTs can be traced back to the

298 ongoing widespread exclusion of this population. Excluding patients with CKD due to

299 possible treatment heterogeneity or initial safety concerns does not necessarily lead to

300 evidence gaps provided that separate RCTs are conducted to assess the efficacy of

301 medications for patients with CKD. However, in practice, only 0.25% of included

302 cardiovascular RCTs was conducted specifically for patients with CKD.

303

304 Implications for practice of the evidence gaps for CVRM medications in patients with CKD

305 Currently, most RCTs which evaluated CVRM medications for patients with CKD focussed

306 on those with CKD stage 3. For patients with CKD stage 4-5, which comprise 10% of the

307 patients with CKD (i.e. 85 million patients) (41), analyses were often absent, particularly for

308 those with a kidney transplant. The lack of RCTs assessing the efficacy of CVRM

309 medications for patients with CKD means that, in practice, practitioners must resort to

310 extrapolating results from RCTs conducted in other populations, assuming that the treatment

311 effects are comparable. However, this assumption is increasingly less likely to hold for

312 patients with more advanced CKD stages where CKD-specific risk factors like vascular

313 calcification, uraemia, chronic inflammation, and immunosuppressive therapy to prevent graft

314 rejection, combined with a very high risk and reduced life expectancy can modify the

315 treatment effect (42, 43).

316

The complexity of extrapolating results to patients with CKD is illustrated by statins. Although these drugs reduce cardiovascular risk in patients with an eGFR <60 ml/min/1.73m², their efficacy has not been demonstrated in individuals with kidney failure (44). The lack of RCTs conducted in patients between these ends of the CKD spectrum makes it impossible to determine the tipping point where statins lose their benefits. Consequently, patients may unintentionally be over- or undertreated since the balance between benefits and side effects remains unknown.

324

In addition to an absolute lack of RCTs, limitations in the analyses further hamper CVRM treatment for patients with CKD. Heterogeneity in exclusion criteria and inadequate reporting of baseline kidney function reduce the comparability of RCTs while the small sample size of strata leads to underpowered analyses and imprecision in effect estimates. Furthermore, the

329 lack of RCTs evaluating the effect of CVRM medications on individual cardiovascular 330 endpoints and kidney endpoints in patients with CKD means that the efficacy of these drugs 331 on these individual endpoints remains unknown. More importantly, stratifying RCT cohorts 332 breaks randomisation and can introduce confounding due to clustering of other CVD risk 333 factors in patients with CKD (45, 46). These limitations are likely to amount in a GRADE 334 recommendation of low or very low certainty of evidence for most CVRM medications in 335 patients with CKD, meaning that their efficacy might be markedly different from the estimated 336 effect (47). 337 338 Implications for research

339

340 An increasing prevalence of CKD (including dialysis and transplantation), the widespread 341 prescription of CVRM medications to this population, and uncertainty about the efficacy of 342 various CVRM medications in patients with CKD underscore the urgency of adequate 343 representation of patients with CKD in cardiovascular RCTs (48, 49). Despite efforts of the 344 United States Food and Drug Administration (FDA) and European Medicine Agency (EMA) to 345 promote the enrolment of patients with CKD and numerous reviews and editorials addressing 346 this issue, the representation of patients with CKD in cardiovascular RCTs has not improved 347 in the past twenty years (12, 13, 50, 51). Bridging the evidence gap for treatment of 348 cardiovascular risk in patients with CKD is the responsibility of different stakeholders 349 including pharmaceutical companies, medicine regulatory authorities, scientific societies, and 350 funding bodies and starts with the proportional inclusion of patients with CKD to enable 351 (subgroup) analyses on kidney disease. New evidence for patients with CKD stage 4-5 352 (including those receiving kidney replacement therapy) should be prioritized considering the 353 evidence gaps are largest for this population. However, such analyses are only feasible if the 354 enrolment of these patient improves and separate RCTs are conducted for them. 355 Additionally, more evidence is needed on the efficacy of CVRM medications on individual 356 cardiovascular and kidney endpoints. Innovative RCT designs like adaptive platform trials

357 based on a master protocol might be an attractive means to rapidly generate evidence for a 358 range of treatment strategies for different groups of patients with CKD. Emulated target trials 359 with real-world data present another opportunity to fill evidence gaps for the efficacy of 360 CVRM medications in patients with CKD, especially for drugs regularly prescribed in practice 361 where conducting new RCTs is prohibitively expensive and time consuming (52). 362 363 Strengths and limitations 364 The main strength of this review is its methodological rigour: we performed screening and 365 data extraction in pairs and published our protocol a priori (17). Unlike previous reviews, we 366 included all CVRM medications recommended in the major American and European 367 guidelines and RCTs evaluating these medications both in primary and secondary prevention 368 settings (18-39). Furthermore, this is the first study to compare the exclusion of patients with 369 CKD with the recommended thresholds for dose-adjustment or contra-indications on kidney 370 function. Limitations of this systematic review are that we might have underestimated the 371 exclusion of patients with CKD in RCTs with ambiguous exclusion criteria such as chronic 372 disease or life-limiting disease and have missed RCTs not registered in ClinicalTrials.gov. 373 However, we are confident the number of missed RCTs is small since the sensitivity of

374 searches in trial registries and electronic databases has demonstrated to be comparable

375 (53). Moreover, our validation study showed that our search strategy identified almost all

376 eligible RCTs from a bibliographic database search. Searching for RCTs registered in or after

377 2000 may appear a limitation as we did not include most RCTs published before this date

378 without retrospective registration. However, these older RCTs are less relevant for

379 contemporary clinical practice and guidelines recommendations as more comprehensive

380 CVRM care and new therapies have vastly improved patients' prognosis (54).

381

382 Conclusion

- 383 The representation of patients with CKD in cardiovascular RCTs has not improved in the past
- 384 twenty years. Cardiovascular RCTs systematically excluded more patients with CKD than
- 385 expected on safety grounds. The lack of cardiovascular RCTs that report results for patients
- 386 with CKD has resulted in significant evidence gaps for the efficacy of most CVRM
- 387 medications in patients with CKD, particularly for those with CKD stage 4-5.
- 388

389 Funding source

- 390 This study was supported by the Dutch CardioVascular Alliance, an initiative with support of
- 391 the Dutch Heart Foundation, 2020B008 RECONNEXT. The sponsor had no role in the
- design, conduct and reporting of the study.
- 393

Other information:

- 395 Registration and protocol
- 396

397 PROSPERO: CRD42022296746

- 398 Protocol: Colombijn JMT, Idema DL, van der Braak K, Spijker R, Meijvis SCA, Bots ML, et al.
- 399 Evidence for pharmacological interventions to reduce cardiovascular risk for patients with
- 400 chronic kidney disease: a study protocol of an evidence map. Syst Rev. 2022;11(1):238.

401

402 **Conflict of Interest Disclosures:**

403 The authors have no conflicts of interest to declare.

404 Availability of data, code, and other materials:

405 All data in this review are based on publicly available articles. Dataset and syntax are 406 available upon request

407

408 **Bibliography**:

- 409 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and
- national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of
 Disease Study 2017. The Lancet. 2020;395(10225):709-33.

412 2. Vaduganathan M, Mensah George A, Turco Justine V, Fuster V, Roth Gregory A. The Global 413 Burden of Cardiovascular Diseases and Risk. Journal of the American College of Cardiology. 414 2022;80(25):2361-71. 415 System USRD. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United 3. 416 States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney 417 Diseases, Bethesda, MD, 2020. 418 4. Thompson S, James M, Wiebe N, Hemmelgarn B, Manns B, Klarenbach S, et al. Cause of 419 Death in Patients with Reduced Kidney Function. J Am Soc Nephrol. 2015;26(10):2504-11. 420 5. de Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screening for chronic kidney disease: 421 where does Europe go? Clin J Am Soc Nephrol. 2008;3(2):616-23. 422 Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, et al. Relative incidence of 6. 423 ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J 424 425 Kidney Dis. 2012;59(1):75-83. 426 7. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. 427 Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 428 2013;382(9889):339-52. 429 8. Dahl H, Sandblost SRT, Welland NL, Sandnes K, Sekse I, Sæle K, et al. Medication Prescription, 430 Common Side-effects, and Nutritional Status are Associated in Patients With Chronic Kidney Disease. 431 Journal of Renal Nutrition. 2022;32(5):520-8. 432 9. Becquemont L, Bauduceau B, Benattar-Zibi L, Berrut G, Bertin P, Bucher S, et al. Association 433 between Cardiovascular Drugs and Chronic Kidney Disease in Non-Institutionalized Elderly Patients. 434 Basic & Clinical Pharmacology & Toxicology. 2015;117(2):137-43. 435 Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical 10. 436 trials in coronary artery disease. Kidney Int. 2006;70(11):2021-30. 437 11. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in 438 randomized controlled trials of cardiovascular disease. Jama. 2006;296(11):1377-84. 439 12. Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, et al. Representation of 440 Patients With Kidney Disease in Trials of Cardiovascular Interventions: An Updated Systematic 441 Review. JAMA Internal Medicine. 2016;176(1):121-4. 442 Maini R, Wong DB, Addison D, Chiang E, Weisbord SD, Jneid H. Persistent 13. 443 Underrepresentation of Kidney Disease in Randomized, Controlled Trials of Cardiovascular Disease in 444 the Contemporary Era. J Am Soc Nephrol. 2018;29(12):2782-6. 445 14. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, et al. Chronic Kidney 446 Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 447 2019;74(14):1823-38. 448 15. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney 449 Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-72. 450 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 451 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 452 17. Colombijn JMT, Idema DL, van der Braak K, Spijker R, Meijvis SCA, Bots ML, et al. Evidence for 453 pharmacological interventions to reduce cardiovascular risk for patients with chronic kidney disease: 454 a study protocol of an evidence map. Syst Rev. 2022;11(1):238. 455 Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC 18. 456 Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the 457 European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of 458 extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: 459 the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral 460 Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for 461 Vascular Surgery (ESVS). European Heart Journal. 2018;39(9):763-816.

462 19. American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment:

463 & lt;em>Standards of Medical Care in Diabetes—2021. Diabetes Care.

464 2021;44(Supplement 1):S111.

465 20. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019
466 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American
467 College of Cardiology. 2019;74(10):e177-e232.

Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC
Guidelines for the management of acute coronary syndromes in patients presenting without
persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes
in patients presenting without persistent ST-segment elevation of the European Society of Cardiology
(ESC). European Heart Journal. 2021;42(14):1289-367.

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines
on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The
Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of
Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart
Journal. 2020;41(2):255-323.

478 23. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al.
479 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery
480 Disease: Executive Summary. Journal of the American College of Cardiology. 2017;69(11):1465-508.

481 24. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 482 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the

483 Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285 484 e350.

485 25. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC
486 Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the
487 European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and
488 management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the
489 special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart
490 Journal. 2021;42(5):373-498.

491 26. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC
492 Guidelines for the management of acute myocardial infarction in patients presenting with ST493 segment elevation: The Task Force for the management of acute myocardial infarction in patients
494 presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart
495 Journal. 2018;39(2):119-77.

496 27. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS
497 Guideline for the Management of Patients With Atrial Fibrillation. Journal of the American College of
498 Cardiology. 2014;64(21):e1-e76.

499 28. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al.
500 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A
501 Guideline From the American Heart Association/American Stroke Association. Stroke.

502 2021;52(7):e364-e467.

503 29. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC
504 Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the
505 diagnosis and management of chronic coronary syndromes of the European Society of Cardiology
506 (ESC). European Heart Journal. 2020;41(3):407-77.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS
Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk:
The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC)
and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC
 Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task
 Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of

514 Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. 515 European Heart Journal. 2021;42(36):3599-726. 516 Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 32. 517 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87-165. 518 33. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA 519 Guideline for the Management of Patients With Valvular Heart Disease. Journal of the American 520 College of Cardiology. 2021;77(4):e25-e197. 521 Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European 34. 522 Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the 523 European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical 524 Practice (constituted by representatives of 10 societies and by invited experts) Developed with the 525 special contribution of the European Association for Cardiovascular Prevention & amp; Rehabilitation 526 (EACPR). European Heart Journal. 2016;37(29):2315-81. 527 35. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International 528 Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. 529 36. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS 530 Guidelines for the management of valvular heart disease: Developed by the Task Force for the 531 management of valvular heart disease of the European Society of Cardiology (ESC) and the European 532 Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2021:ehab395. 533 37. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC 534 Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-535 337. 536 38. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 537 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, 538 Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American 539 College of Cardiology. 2018;71(19):e127-e248. 540 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH 39. 541 Guidelines for the management of arterial hypertension: The Task Force for the management of 542 arterial hypertension of the European Society of Cardiology (ESC) and the European Society of 543 Hypertension (ESH). European Heart Journal. 2018;39(33):3021-104. 544 Ashley C, Dunleavy A. The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal 40. 545 Practitioners. 5th Edition ed: CRC press; 2018. 546 41. Sundström J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, 547 outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million 548 patients from 11 countries: The CaReMe CKD study. The Lancet Regional Health – Europe. 2022;20. 549 42. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: 550 Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the 551 American Heart Association. Circulation. 2019;139(16):e840-e78. 552 43. Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, et al. Cardiovascular 553 outcome trials in patients with chronic kidney disease: challenges associated with selection of 554 patients and endpoints. Eur Heart J. 2019;40(11):880-6. 555 44. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? QJM: 556 An International Journal of Medicine. 2017;110(8):493-500. 557 VanderWeele TJ, Knol MJ. Interpretation of subgroup analyses in randomized trials: 45. 558 heterogeneity versus secondary interventions. Ann Intern Med. 2011;154(10):680-3. 559 46. Groenwold RH, Donders AR, van der Heijden GJ, Hoes AW, Rovers MM. Confounding of 560 subgroup analyses in randomized data. Arch Intern Med. 2009;169(16):1532-4. 561 47. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. 562 Introduction—GRADE evidence profiles and summary of findings tables. Journal of Clinical 563 Epidemiology. 2011;64(4):383-94. 564 48. Wang JH, Hart A. Global Perspective on Kidney Transplantation: United States. Kidney360. 565 2021;2(11).

566 49. Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global Epidemiology of

567 End-Stage Kidney Disease and Disparities in Kidney Replacement Therapy. American Journal of 568 Nephrology. 2021;52(2):98-107.

569 50. Food and Drug Administration. Guidance for Industry Pharmacokinetics in Patients with 570 Impaired Renal Function – Study Design, Data Analysis, and Impact on Dosing. 2020.

571 51. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of 572

medicinal products in patients with decreased renal function. 2015 16 March 2023.

573 Sendor R, Stürmer T. Core concepts in pharmacoepidemiology: Confounding by indication 52. 574 and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31(3):261-9.

575 53. Knelangen M, Hausner E, Metzendorf MI, Sturtz S, Waffenschmidt S. Trial registry searches

576 for randomized controlled trials of new drugs required registry-specific adaptation to achieve

577 adequate sensitivity. J Clin Epidemiol. 2018;94:69-75.

578 54. ClinicalTrials.gov. 2021 [Available from: https://clinicaltrials.gov/ct2/manage-recs/fdaaa. 579

581 Tables

582

583 Table 1: characteristics of included RCTs

Variables	All (n=1194)	Exclusion of people with CKD (n=884)	No exclusion of people with CKD (n=310)
Study characteristics			
Year of publication <2000 2000-2005 2006-2010 2011-2015 2016-2020 >2020	21(2) 50 (4) 239 (20) 393 (33) 418 (35) 73 (6)	12 (1) 33 (4) 173 (20) 286 (32) 322 (36) 58 (7)	9 (3) 17 (5) 66 (21) 107 (34) 96 (31) 15 (5)
Sample size Total Median [IQR] Follow-up (months) Only protocol published	2207677 568 [304 – 1315] 24.0 [12.0 – 39.6] 81 (7)	1.595.831 559 [311 – 1250] 26.4 [12.0 – 40.8] 64 (8)	563.038 530 [280 – 1288] 17.8 [5.5 – 30.0] 17 (5)
Location Multi-continental Europe North America Asia/Australia/Africa/Other	576 (48) 165 (14) 172 (14) 281 (24)	443 (50) 117 (13) 116 (13) 208 (24)	133 (43) 48 (16) 53 (17) 73 (24)
Funding source [*] Industry Government Institutional Unspecified/miscellaneous	987 (83) 81 (7) 151 (13) 49 (4)	736 (83) 57 (8) 110 (12) 35 (4)	251 (81) 24 (6) 41 (13) 14 (5)
Type of intervention Antihypertensives Glucose lowering drugs Lipid lowering drugs Antiplatelets or anticoagulants Combination of interventions	221 (19) 552 (46) 162 (14) 229 (19) 30 (3)	182 (20) 424 (48) 126 (15) 132 (15) 20 (2)	39 (13) 128 (41) 36 (12) 97 (31) 10 (3)
Participant characteristics			
Age (years)	63 ± 6	64 ± 6	62 ± 6
Sex (% female) eGFR (ml/min/1.73m ²)* mean (SD) Not reported ≥90, 60-89 45-59 30-44 15-29 Serum creatining (max/dl.)*	36 ± 12 73 ± 13 899 (75) 79 (27) 169 (57) 27 (9) 13 (4) 7 (2)	$\begin{array}{c} 37 \pm 12 \\ 73 \pm 13 \\ 623 (71) \\ 74 (28) \\ 144 (55) \\ 24 (9) \\ 13 (5) \\ 6 (3) \end{array}$	$\begin{array}{c} 33 \pm 12 \\ 77 \pm 10 \\ 276 (89) \\ 5 (14) \\ 25 (73) \\ 3 (8) \\ 0 (0) \\ 1 (3) \end{array}$
Serum creatinine (mg/dL)* Median [IQR] Not reported <1.0 1.0-1.49 1.5-2.00 >2.0 Dialysis	1.00 [0.96 – 1.04] 1040 (87) 77 (50) 61 (40) 9 (6) 7 (5) 17 (<1)	1.00 [0.97 – 1.04] 750 (85) 67 (50) 51 (38) 9 (7) 7 (5) 17 (2)	$\begin{array}{c} 1.00 \; [0.95-1.01] \\ 290 \; (94) \\ 10 \; (50) \\ 10 \; (50) \\ 0 \; (0) \\ 0 \; (0) \\ 0 \; (0) \end{array}$
Transplantation	1 (<1)	1 (<1)	0 (0)

584 585 586 587 588 Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range. Categorical variables are describes as n (percentage). Normally distributed continuous variables as mean ± SD and skewedly distributed variables as median [IQR].

RCTs can have multiple funding sources. Therefore percentages do not add up to 100 percent.

*percentages only for proportion without missing eGFR or serum creatinine.

589

590

592 Figures

593 Figure 1: Overview of the exclusion of people with CKD from cardiovascular RCTs. Panel A shows the 594 percentage of RCTs that exclude (subgroups of) people with different stages of CKD over time; panel B shows 595 the exclusion of people with CKD for different types of CVRM medications; panel C shows the most commonly 596 used exclusion criteria for eGFR (ml/min/1.73m²), serum creatinine (mg/dL), and other kidney exclusion criteria, 597 respectively. 598 599 Abbreviations: 600 ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel 601 blocker; CKD, chronic kidney disease; DOAC, direct oral anticoagulants; DPP-4 receptor agonist, dipeptidyl-602 peptidase-4 inhibitors; eGFR, estimated glomerular filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 603 receptor agonist; MRA, mineralocorticoid receptor antagonist; PSCK-9 inhibitor, proprotein convertase 604 subtilisin/kexin type 9 inhibitor; SCr, serum creatinine; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor. 605 606 Other eGFR exclusion criteria were eGFR <40 (n=8); <25 (n=7); >60 and <30, <35 (both n=5); eGFR >50, >60 607 (both n=3); eGFR <36, >30, >70 and <20, >60 and <15, >60 and <45, creatinine clearance <60% of the normal 608 age-adjusted value (all n=2); eGFR <10, >45 and <20, >45 and <25, >50 and <30, >60 and <25, >75 and, <25, 609 >80 and <20, >90 and <25, >90 and <30, <70, <90, not satisfying eGFR (all n=1). Other serum creatinine 610 exclusion criteria were serum creatinine >1.3 (M) >1.2 (F) (n=7); serum creatinine >1.5 (M) >1.2 (F) (n=6); serum 611 creatinine >1.5 (M) >1.3 (F) (n=5); serum creatinine >1.4, >2.3, elevated serum creatinine level (all n=4); serum 612 creatinine >4, (not further specified; n=3); serum creatinine >1.5 times ULN (M), > 1.4 times ULN (F); >1.5 times 613 ULN, >2 times ULN, >3 times ULN, >1.6, >1.8, >2 (M) >1.8 (F), >3 and <1.5 (M), >3 and <1.3 (F) (all n=2); <1.7 614 (M) <1.5 (F); serum creatinine <2, >2.5 and <1.2 (M), <1.0 (F), >5, and <1.5, >1.7 (M) >1.5 (F), >1.5 (M) >1.1 (F), 615 >1.6 (M) >1.5 (F), >2 (M) >1.5 (F), >2 (M) >1.7 (F), >2.2, >2.4, >2.4 (M) > 2.0 (F), >2.7, >3.5, >6 (all n=1). Other 616 kidney exclusion criteria were not receiving dialysis (n=8); abnormal laboratory results on kidney function tests 617 (not further specified; n=4); serum creatinine or creatinine clearance that was a contraindication to metformin 618 according to the country-specific label (n=2); expected Kidney transplant within 1 year and not on dialysis, 619 patients with serious kidney damage, renal artery stenosis in a solitary kidney or kidney transplant or, one 620 functioning kidney, no kidney transplant, polycystic kidney disease, unsuccessful kidney transplantation (all n=1). 621 622 Figure 2: Exclusion of patients with CKD stratified by prescription recommendations for patients with CKD. Panel 623 A shows the percentage of RCTs that exclude different subgroups of patients with CKD stratified by

624 recommendations for dose-adjustment or contra-indications; panel B shows the percentage of RCTs over time

625 where dose adjustment is recommended.

626	Abbreviations: CKD, chronic kidney disease
627	
628	Figure 3: Number of RCTs with analyses for people with CKD for different types of CVRM medications. panel A
629	shows the number of analyses for people with CKD for different cardiovascular endpoints; Panel B shows the
630	percentage of RCTs with analyses for people with any CKD and CKD stage 4-5.
631	
632	Abbreviatons:
633	CAD, coronary artery disease; CeVD, cerebrovascular disease; CKD, chronic kidney disease; MACE, major
634	adverse cardiovascular event; PAD, peripheral arterial disease.
635	
636	Figure 4: Heat map of (subgroup) analyses for major adverse cardiovascular events for people with different
637	stages of CKD.
638	Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,
639	angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;
640	DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular
641	filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor
642	antagonist; PCSK-9 inhibitor, proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet
643	therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,
644	vitamin K antagonist.
645	
646	Figure 5: Overview of individual studies with analysis on eGFR or kidney replacement therapy for major adverse
647	cardiovascular events in patients with CKD. Panel A illustrates analyses for antithrombotics; panel B for blood-
648	pressure-lowering drugs; panel C for cholesterol-lowering drugs; panel D for glucose-lowering drugs; and panel E
649	for polypills.
650	
651	Abbreviations:
652	ACE-inhibitor/ACE-I, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CAA, centrally-acting
653	antihypertensive; CCB, calcium channel blocker; CKD, chronic kidney disease; DAPT, double antiplatelet therapy;
654	DOAC, direct oral anticoagulants; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitor; eGFR, estimated glomerular
655	filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; KRT, kidney replacement
656	therapy; MRA, mineralocorticoid receptor antagonist; PCSK-9 inhibitor, proprotein convertase subtilisin/kexin type
657	9 inhibitor; SAPT, single antiplatelet therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT,

658 triple antiplatelet therapy; VKA, vitamin K antagonist.

659

660 Supplementary Figures

- 661 **Supplementary Figure 1:** Flow chart of literature search.
- 662 **Supplementary Figure 2:** Exclusion of patients with CKD stratified by prescription recommendations for patients

663 with CKD.

- 664 **Supplementary Figure 3:** Heat map of (subgroup) analyses for all-cause mortality for people with different
- 665 stages of CKD.
- 666 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,
- angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;
- 668 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular
- 669 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor
- 670 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet
- 671 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,
- 672 vitamin K antagonist.
- 673
- 674 Supplementary Figure 4: Heat map of (subgroup) analyses for cardiovascular mortality for people with different675 stages of CKD.
- 676 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,
- 677 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;
- 678 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular
- 679 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor
- 680 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet
- 681 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,
- 682 vitamin K antagonist.
- 683

- 686 Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,
- 687 angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;
- 688 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular
- 689 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor
- 690 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet
- 691 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,
- 692 vitamin K antagonist.

Supplementary Figure 5: Heat map of (subgroup) analyses for coronary artery disease for people with different
 stages of CKD.

694	Supplementary Figure 6: Heat map of (subgroup) analyses for heart failure for people with different stages of		
695	CKD.		
696	Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,		
697	angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;		
698	DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular		
699	filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor		
700	antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet		
701	therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,		
702	vitamin K antagonist.		
703			
704	Supplementary Figure 7: Heat map of (subgroup) analyses for cerebrovascular disease for people with different		
705	stages of CKD.		
706	Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,		
707	angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;		
708	DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular		
709	filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor		
710	antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet		
711	therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,		
712	vitamin K antagonist.		
713			
714	Supplementary Figure 8: Heat map of (subgroup) analyses for peripheral arterial disease for people with		
715	different stages of CKD.		
716	Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,		
717	angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;		
718	DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular		
719	filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor		
720	antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet		
721	therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,		
722	vitamin K antagonist.		
723			
724	Supplementary Figure 9: Heat map of (subgroup) analyses kidney failure for people with different stages of		
725	CKD.		
726	Abbreviations: ACE-inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,		
727	angiotensin receptor-neprilysin inhibitor; CCB, calcium channel blocker; DAPT, double antiplatelet therapy;		

- 728 DOAC, direct oral anticoagulant; DPP-4 inhibitor, dipeptidyl-peptidase-4 inhibitors; eGFR, estimated glomerular
- 729 filtration rate; GLP-1 receptor agonist, glucagon-like peptide-1 receptor agonist; MRA, mineralocorticoid receptor
- 730 antagonist; PCSK-9 inhibitor, Proprotein convertase subtilisin/kexin type 9 inhibitor; SAPT, single antiplatelet
- 731 therapy; SGLT-2 inhibitor, sodium-glucose cotransporter-2 inhibitor; TAPT, triple antiplatelet therapy; VKA,
- vitamin K antagonist.



Α

Exclusion criteria











A Acetylsalicylic acid PEGASUS-TIMI 54 (1; n = 21162) COMPASS (1; n = 27395) HOT (n = 18790) HOST-EXAM (1; n = 5438) VOYAGER-PAD (1; n = 6564) P2Y12 inhibitor EUCLID (n = 13884) PLATO (n = 18624) TRITON-TIMI 38 (n = 12204) HOST-EXAM (2; n = 5438) TWILIGHT (1; n = 2690) SMART-CHOICE (1; n = 2993) ISAR-REACT 5 (n = 4018) CREDO (n = 2116) PRAGUE 18 (n = 1230) POPular-TAVI (n = 313) Other SAPT TRA 2°P-TIMI 50 (n = 12944) TRA•CER (n = 25449) Packham 2012 (n = 1248) DOAC ATLAS ACS-TIMI 46 (n = 15526) ROCKET-AF (1; n = 14264) ENGAGE-AF-TIMI 48 (1; n = 21026) ARISTOTLE (1; n = 18201) COMMANDER-HF (n = 5022) AFIRE (1; n = 2215) ATLAS ACS-2-TIMI 51 (n = 3491) ENVISAGE-TAVI-AF (1; n = 1426) ENSURE-AF (1; n = 2199) APPRAISE 2 (n = 1715) RENAL-AF (1; n = 154) VALKYRIE (1; n = 132) Vitamin K antagonist ROCKET-AF (2; n = 14264) ENGAGE-AF-TIMI 48 (2; n = 21026) ARISTOTLE (2; n = 18201) ENVISAGE-TAVI-AF (2; n = 1426) ENSURE-AF (2; n = 2199) RENAL-AF (2; n = 154) VALKYRIE (2; n = 132) DAPT PEGASUS-TIMI 54 (2; n = 21163) GLOBAL LEADERS (n = 15991) TRILOGY-ACS (n = 7243) STOP-DAPT-2 (n = 3009) CSPS.com (1; n = 1879) HOST-ASSURE (1; n = 3755) TWILIGHT (2; n = 2620) SMART-CHOICE (2; n = 2993) TICO (n = 3056) HOST-REDUCE-POLYTECH-ACS (n = 2338) PRODIGY (n = 1970) REDUCE (n = 1496) CLEAN (n = 931) TAPT COMPASS (1; n = 27395) CSPS.com (2; n = 1879) HOST-ASSURE (2; n = 3755) SAPT + DOAC COMPASS (2; n = 27395) VOYAGER-PAD (2; n = 6564) RE-DUAL-PCI (1; n = 2215) AFIRE (2; n = 2215)

DAPT + VKA

90 75 60 45 eGFR or KRT 30 15 0



